Investigation announced for Investors in Theratechnologies Inc. (NASDAQ: THTX) shares over potential Wrongdoing

An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Theratechnologies Inc.

Investors who purchased shares of Theratechnologies Inc. (NASDAQ: THTX) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Theratechnologies officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.

Canada based Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. Theratechnologies Inc. reported that its Total Revenue rose from $66.05 million for the 12 months period that ended on November 30, 2020, to $69.82 million for the 12 months period that ended on November 30, 2021, and that its Net Loss over those time periods increased from $22.66 million to $31.72 million.

On December 1, 2022, Theratechnologies Inc. issued a press release "announc[ing] that it has decided to pause the enrollment of patients in its Phase 1 clinical trial of TH1902, the Company's lead investigational peptide drug conjugate (PDC) for the treatment of sortilin-expressing cancers." Theratechnologies Inc. explained that it "voluntarily made the decision to pause enrollment and revisit the study design after consulting with its investigators. Efficacy results observed thus far were not convincing enough to pursue enrolling patients and did not outweigh the adverse events seen in some patients. As previously reported, these adverse events consist mainly of neuropathy and eye toxicity."

Shares of Theratechnologies Inc. (NASDAQ: THTX) declined from $3.26 per share in February 01, 2022, to $0.77 per share on December 20, 2022.

Those who purchased shares of Theratechnologies Inc. (NASDAQ: THTX) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.